#drug-pricing

#drug-pricing

"FDA policymakers have tried to come up with ideas to speed important products to market. ... It is in part directed to achieving some of the (Trump) Administration's goals," said Chad Landmon, chair of Polsenelli's patent and FDA practice.

PRESIDENT DONALD TRUMP: I will tell you that we are going to be doing numbers on the cost of drugs in this country, that it's I'm not talking about a 20 percent decrease, which would be good. I'm talking about 1,000 percent decrease. We're talking about where a product would sell for $80 in Germany, and $1,300 here, and we're not going to do that.

CVS Health's decision is a clear violation of the ACA's requirement to cover USPSTF-recommended preventive services, including PrEP. The entire world is excited by this drug and its potential contribution to preventing and eventually ending HIV. However, a drug will only work if people can access it and right now CVS Health, which owns the largest pharmacy benefit manager in the country, is shamefully blocking people from taking it, unlike other payers.

Hikma's generic Vascepa, with its "skinny label," poses a challenge for patent protection, potentially undermining the incentives for innovation in the pharmaceutical industry.

"The group does not include any contact information or details about membership on its website. Seniors 4 Better Care is reportedly a 'shell group' for the American Prosperity Alliance."

Senate Democrats and the Biden administration abandoned plans to cap drug prices based on payments in other wealthy nations during negotiations to empower Medicare's negotiation capabilities.

Trump's executive order asks drugmakers to voluntarily lower pharmaceutical costs for U.S. consumers, but lacks a definitive mechanism for enforcing these reductions.